120 results on '"Filippatos, Gerasimos"'
Search Results
2. Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure.
3. Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled.
4. Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.
5. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes.
6. Decongestion with Acetazolamide in Acute Decompensated Heart Failure across the Spectrum of Left Ventricular Ejection Fraction: a Pre-specified Analysis from the ADVOR trial.
7. Empagliflozin in Black Versus White Patients with Heart Failure: Analysis of EMPEROR-Pooled.
8. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes.
9. Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.
10. Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes.
11. Toward a Universal Definition of Etiologies in Heart Failure: Categorizing Causes and Advancing Registry Science.
12. Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial.
13. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
14. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
15. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.
16. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.
17. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
18. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
19. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.
20. Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial.
21. Inhibition of the renin-angiotensin system in the cardiorenal syndrome with anaemia: a double-edged sword.
22. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.
23. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.
24. Immunosenescence in patients with chronic systolic heart failure.
25. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure Rationale and Design of the Randomized Trial to REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I).
26. Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study.
27. Effects of levosimendan on markers of kidney function in patients with acutely decompensated heart failure and renal impairment.
28. Response by Filippatos et al to Letter Regarding Article, "Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes".
29. B-type natriuretic peptide vs. cardiac risk scores for prediction of outcome following major orthopedic surgery.
30. Natriuretic peptides revisited: new potentials and challenges in heart failure.
31. Plasma activity of B-type natriuretic peptide in patients with biventricular heart failure versus those with right heart failure due to chronic obstructive pulmonary disease.
32. Increased 90-Day Mortality in Patients With Acute Heart Failure With Elevated Copeptin.
33. Beneficial association of β-blocker therapy on recovery from severe acute heart failure treatment: Data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial.
34. Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes.
35. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes.
36. Prevalence of paroxysmal atrial fibrillation in Brugada syndrome: a case series and a review of the literature.
37. Pathophysiology of peripheral muscle wasting in cardiac cachexia.
38. Abstract 16180: Characteristics of NYHA I Patients Receiving CRT - The ESC/EHRA CRT Survey II.
39. Abstract 16148: CRT in Atrial Fibrillation: More Often Than Anticipated! Evidence From the Second ESC/EHRA CRT Survey.
40. Abstract 14794: Is Plasma Renin Activity Associated With Worse Outcomes in Acute Heart Failure? A Secondary Analysis From the BLAST-AHF Trial.
41. Updated Clinical Practice Guidelines on Heart Failure: An International Alignment.
42. Real-time 3-dimensional transesophageal echocardiography: precise evaluation of a rocking mitral annuloplasty ring.
43. Serum Chloride and the Response to Acetazolamide in Patients With Acute Heart Failure and Volume Overload: A Post Hoc Analysis From the ADVOR Trial.
44. Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial.
45. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
46. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.
47. Risk of Heart Failure and Death After Prolonged Smoking Cessation: Role of Amount and Duration of Prior Smoking.
48. Third universal definition of myocardial infarction.
49. Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure.
50. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.